Psychology Wiki

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Clinical: Approaches · Group therapy · Techniques · Types of problem · Areas of specialism · Taxonomies · Therapeutic issues · Modes of delivery · Model translation project · Personal experiences ·


Progressive supranuclear palsy
ICD-10 G231
ICD-9 333.0
OMIM 601104
DiseasesDB 10723
MedlinePlus [1]
eMedicine neuro/328
MeSH {{{MeshNumber}}}

Progressive supranuclear palsy (PSP) (or the Steele-Richardson-Olszewski syndrome, after the Canadian physicians who described it in 1963[2] [3]) is a rare degenerative disorder involving the gradual deterioration and death of selected areas of the brain.

The sexes are affected approximately equally and there is no racial, geographical or occupational predilection. Approximately 6 people per 100,000 population have PSP.

Symptoms and signs[]

The initial symptom in two-thirds of cases is loss of balance and falls. Other common early symptoms are changes in personality or general slowing of movement.

Later symptoms and signs are dementia (typically including loss of inhibition and ability to organize information), slurring of speech, difficulty swallowing, and difficulty moving the eyes, most specifically in the downward direction.

Some of the other signs are poor eyelid function, contracture of the facial muscles, a backward tilt of the head with stiffening of the neck muscles, sleep disruption, urinary incontinence and constipation.

Prognosis[]

There is currently no effective treatment for PSP, although some of the symptoms can respond to nonspecific measures. The average age at symptoms onset is 63 and survival from that point averages 7 years with a wide variance.

Differential diagnosis[]

PSP is frequently misdiagnosed as Parkinson's disease because of the slowed movements and gait difficulty, or as Alzheimer's Disease because of the behavioral changes. It is one of a number of diseases collectively referred to as Parkinson plus syndromes.

Pathophysiology[]

The affected brain cells are both neurons and glial cells. The neurons display neurofibrillary tangles, which are clumps of tau protein, a normal part of brain cell's internal structural skeleton.

The principal areas of the brain affected are:

Genetics[]

Fewer than 1% of those with PSP have a family member with the same disorder. A variant in the gene for tau protein called the H1 haplotype, located on chromosome 17, has been linked to PSP. Nearly all people with PSP received a copy of that variant from each parent, but this is true of only about two-thirds of the general population. Therefore, the H1 haplotype appears to be necessary but not sufficient to cause PSP. Other genes and environmental toxins are being investigated as other contributors to the cause of PSP.


Support groups[]

Several international organizations serve the needs of patients with PSP and their families and support research. The Society for PSP ("CurePSP") is based in the US and the PSP Association is based in the UK.

See also[]

Reference[]

  1. ^  Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of "heterogeneous system degeneration". Trans Am Neurol Assoc 1963;88:25-9. PMID 14272249.
  2. ^  Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359. PMID 14107684.
  3. ^  OMIM 601104

External links[]

  1. REDIRECT Template:CNS diseases of the nervous system


This page uses Creative Commons Licensed content from Wikipedia (view authors).